VCU Massey Comprehensive Cancer Center | Strategic Alliance Partners

Victor Y. Yazbeck, MD, discusses the potential for venetoclax and idelalisib, both as single agents and in combination with other agents, and what questions remain regarding both therapies in CLL.

The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in women’s health research.

OncLive® announced an addition to its vibrant Strategic Alliance Partnership program today as VCU Massey Cancer Center signed onto the program's mission to raise awareness of cancer treatment and research.